Most bladder cancer symptoms show up in the urine rather than as pain, and the one that matters most is also the easiest to dismiss: visible blood that appears once and then vanishes. Bleeding from a bladder tumor is intermittent by nature, so a single pink or cola-colored episode that clears on its own still deserves evaluation. At the same time, blood detected only under a microscope on a routine urinalysis is common and usually has a harmless explanation. In this article you will learn which urinary changes deserve attention, how doctors weigh age and smoking history when blood shows up on a lab report, how the diagnosis is made, and what the two main forms of the disease mean for treatment and follow-up.
What bladder cancer is and who it affects
The bladder is a hollow muscular organ that stores urine. Its inner surface is lined with urothelial cells, a stretchy layer that expands as the bladder fills. Most bladder cancers start in that lining and are called urothelial carcinoma, once known as transitional cell carcinoma.
Why the lining matters
Because the bladder holds urine for hours, its lining stays in contact with whatever the kidneys filter out of the blood, including chemicals from cigarette smoke or the workplace. That is also why the first sign of trouble usually appears in the urine rather than as a lump or an ache.
Who is most often affected
The disease is diagnosed far more often after age 55, and more often in men. Women are not spared, and their symptoms are more often blamed at first on a urinary tract infection, which delays diagnosis.
Bladder cancer symptoms you should not ignore
Painless visible blood in the urine
Blood you can see, without burning or pain, is the classic presentation of bladder cancer. Urine may look pink, rusty, tea-colored, or frankly red. Because there is no discomfort, many people write it off as a passing oddity. It is not something to wait out. Readers wanting more detail can consult a dedicated explainer on blood in the urine.
When the bleeding stops on its own
This is the most important point in the article. A bladder tumor bleeds in episodes: a day of bleeding, weeks of nothing, then bleeding again. The blood disappearing does not mean the cause has. Guidelines treat a single episode of visible hematuria as a reason for evaluation, even if later samples look normal. Waiting for it to come back is the most common way early bladder cancer gets missed.
Irritative symptoms that resemble an infection
Some tumors, particularly flat lesions known as carcinoma in situ, cause urgency, frequency, and burning without much visible blood. These overlap almost perfectly with cystitis and often improve briefly with antibiotics before returning. If symptoms recur while urine cultures stay negative, that pattern deserves a second look rather than another prescription. It helps to understand how a urinary tract infection is normally diagnosed and treated, and that a positive dipstick can reflect inflammation rather than bacteria, as covered in a breakdown of leukocyte esterase results.
Signs that suggest more advanced disease
Less commonly, the disease is found after symptoms of growth beyond the lining: pain low in the back or on one side, difficulty passing urine, leg swelling, weight loss, or bone pain. Ongoing blood loss can also cause anemia, so a low red cell count on a standard complete blood count panel occasionally gives the first clue, for reasons set out in an overview of anemia and its causes.
Microscopic hematuria on a urinalysis: putting the risk in context
Many people arrive here for a different reason: a routine lab report showed red blood cells in urine that looked normal to the eye. This is microscopic hematuria, and it is common. Usually the cause is benign, such as vigorous exercise, menstruation, a recent infection, kidney stones, or an enlarged prostate. Cancer accounts for a small minority of cases.
The finding is not meaningless either. US guidance from the American Urological Association, revised in 2025, sorts people into risk groups rather than treating everyone the same. Three things drive that: age, smoking history, and how many red blood cells the laboratory counted.
| Risk group | Typical profile | What evaluation usually involves |
|---|---|---|
| Low | Younger adult, never smoked or smoked very little, only a few red blood cells | Repeat urinalysis; imaging and cystoscopy discussed as an option |
| Intermediate | Middle age, moderate lifetime smoking, or a higher red blood cell count | Imaging of the kidneys and ureters plus cystoscopy, arranged by a urologist |
| High | Older adult, heavy smoking history, or many red blood cells per field | CT urography and cystoscopy, without delay |
Two things follow. If you are young and never smoked, a trace of blood on one sample most likely has a benign explanation, and a repeat test is often the next step. If you are older with a substantial smoking history, the same result warrants a look inside the bladder. Before your appointment it is worth reading a plain-language guide to urine test results and an explanation of urine microscopy findings, along with the formation and passage of kidney stones, another frequent source of blood in urine.
What causes bladder cancer: smoking, chemicals and other risk factors
Smoking is the dominant factor
According to the Centers for Disease Control and Prevention, smoking is the most important risk factor for bladder cancer. Carcinogens from tobacco smoke are filtered by the kidneys and concentrate in urine that sits against the bladder lining. Risk rises with years smoked and amount per day, and falls after quitting without reaching never-smoker levels for a long time. The same exposure drives risk elsewhere, as described in a companion article on lung cancer.
Occupational exposures most people have never heard of
A second cause is underappreciated outside occupational medicine: aromatic amines, industrial chemicals long used in dyes and rubber processing. Higher-exposure groups include painters, hairdressers, printers, and workers in rubber, leather, textile, dye, and petroleum industries. Arsenic in well water also contributes. Because the delay stretches across decades, a job held in your twenties can matter to a diagnosis in your sixties, which is why urologists ask about your whole work history.
Other contributors
- Age above 55 and male sex.
- Chronic bladder irritation: long-term catheter use, recurrent infections, or schistosomiasis.
- Previous pelvic radiation or certain chemotherapy drugs.
- A family history, or inherited conditions such as Lynch syndrome.
Prevention follows from that list: not smoking, and respecting workplace protection around solvents and dyes.
How bladder cancer is diagnosed
Why there is no screening program
Unlike breast, cervical, colorectal, and lung cancer, bladder cancer has no population screening program in the United States. The US Preventive Services Task Force has found the evidence insufficient to recommend routine testing of adults without symptoms. Early detection therefore depends almost entirely on symptoms being reported and taken seriously.
Urinalysis and urine cytology
The workup starts with a urinalysis, which confirms blood and screens for infection; if infection is suspected, a urine culture and its interpretation settles it. Urine cytology has a pathologist look for abnormal cells shed from the lining. It detects high-grade cancer well but often misses low-grade tumors, so a normal result never rules the disease out.
Imaging the upper urinary tract
CT urography combines a computed tomography scan with contrast dye to image the kidneys, ureters, and bladder, looking for tumors higher up and other explanations such as stones. People with reduced kidney function may be offered ultrasound or magnetic resonance imaging instead, and function is checked beforehand with a blood creatinine measurement.
Cystoscopy, the definitive test
Cystoscopy confirms or excludes a bladder tumor. A thin flexible instrument with a camera passes through the urethra so the urologist can inspect the lining directly and biopsy anything suspicious. It is done under local anesthetic in an office, though most people find the prospect unpleasant. No urine test matches its accuracy, which is why it remains the reference standard.
Urine tumor-marker tests and their honest limits
Several commercial urine tests look for tumor proteins or genetic changes shed into urine. Some outperform cytology, but accuracy varies widely between products and none is reliable enough to replace cystoscopy. Current guidance treats them as a complement that may reduce how often camera examinations are needed. A negative result does not close the file.
Non-muscle-invasive versus muscle-invasive disease
This split determines almost everything that follows. It describes how deeply the tumor has grown into the bladder wall.
| Feature | Non-muscle-invasive | Muscle-invasive |
|---|---|---|
| Depth of growth | Confined to the lining and the layer just beneath it | Has grown into the muscle wall of the bladder or beyond |
| Share of cases at diagnosis | Roughly three quarters | Roughly one quarter |
| Main treatment approach | Removal through the urethra, then medication placed into the bladder | Bladder removal, or chemotherapy with radiation to preserve it |
| Main long-term concern | Frequent recurrence, and possible progression | Spread outside the bladder |
| Follow-up | Repeated cystoscopy over many years | Imaging and clinical review on a set schedule |
Within the non-muscle-invasive group, doctors also separate low-grade from high-grade tumors and identify carcinoma in situ, a flat high-grade lesion that looks unremarkable but behaves aggressively. Grading, not just stage, decides how intensive treatment must be.
Treatment options at each stage
Transurethral resection
Transurethral resection of bladder tumor, abbreviated TURBT, is both the first treatment and a diagnostic step. Through the urethra, with no external incision, the surgeon removes the visible tumor and samples the muscle beneath so the pathologist can judge invasion depth. A single dose of chemotherapy is often instilled afterward.
Medication placed inside the bladder
For intermediate and high-risk non-muscle-invasive disease, the standard follow-on treatment is bacillus Calmette-Guerin, or BCG: a weakened bacterium related to the one causing tuberculosis, delivered as a liquid through a catheter. It provokes a local immune response against remaining cancer cells. Given weekly at first, then intermittently for months or years, it commonly causes urgency, burning, and flu-like symptoms afterward.
There is a practical complication worth knowing. BCG is made by very few manufacturers, and global shortages have recurred for more than a decade. Clinics respond by prioritizing the highest-risk patients, reducing doses, or substituting chemotherapy instilled into the bladder. If your schedule is altered for supply reasons, that is a recognized situation rather than an arbitrary decision.
Removing the bladder
Muscle-invasive disease is usually treated with radical cystectomy, removal of the bladder with nearby lymph nodes, generally after chemotherapy. Urine is then rerouted into a segment of bowel draining to an opening on the abdomen, or into a reconstructed internal reservoir. For selected patients a bladder-preserving combination of resection, chemotherapy, and radiation is worth discussing. Kidney function is monitored closely afterward.
Advanced and metastatic disease
Treatment of cancer that has spread has changed substantially. Immune checkpoint inhibitors release a brake on the immune system so it can recognize tumor cells. Antibody-drug conjugates attach a chemotherapy payload to an antibody that targets a protein on cancer cells, concentrating the drug where it is needed. Targeted drugs for tumors with specific genetic changes add another option. All bring side effects, particularly skin and nerve problems.
Recurrence, surveillance and when to see a doctor
Non-muscle-invasive bladder cancer recurs often, which is why surveillance is lifelong: cystoscopy every three months at first, spaced out gradually if everything stays clear, with periodic urine testing and imaging. Many patients describe this as the hardest part of the illness, not the diagnosis itself but the recurring appointments and the anxiety before each one. Knowing the schedule in advance and treating the visits as maintenance rather than verdicts both help. Men whose follow-up also covers the prostate may find a separate guide to prostate cancer useful.
Reasons to contact a clinician promptly
- Visible blood in your urine, at any age, even once, even if it clears the next day.
- A urinalysis reporting red blood cells if you are over 55 or have smoked substantially.
- Urgency, frequency, or burning that keeps returning while urine cultures stay negative.
- Difficulty passing urine, or a bladder that never feels empty.
- Persistent flank, lower back, or pelvic pain with urinary changes.
- Unexplained weight loss or fatigue alongside any of the above.
Seek urgent care if you are passing large clots, cannot urinate, or feel faint after heavy bleeding.
Latest scientific advances
Recent research has focused on two questions that matter directly to patients: who really needs an invasive evaluation, and how follow-up can be made less burdensome.
Putting microscopic blood in perspective
A hospital review of more than four thousand people with blood detectable only under the microscope found fewer than two in a hundred had a urothelial tumor, meaning a cancer of the urinary tract lining. Risk clustered in older patients, men, heavy smokers, and those with higher red blood cell counts, confirming that the risk-based approach works. The authors also found women over 70 had a rate high enough to argue for treating them as high risk. What this means for you: if you are young and never smoked, microscopic blood is very unlikely to be cancer; if you are older or smoked heavily, it deserves prompt attention.
Urine tests are improving, but do not yet replace the camera
A systematic review, meaning a study that pools and appraises all published evidence on a question, compared twenty-one urine biomarker tests against cystoscopy in people already treated for bladder cancer. Accuracy varied enormously, and the reviewers concluded these tests should complement cystoscopy rather than replace it. A pooled analysis of one genetic urine test found it detected most cancers and correctly reassured most people without disease, while still missing some; the authors called the data limited. What this means for you: a urine test may reduce how many camera examinations you need, but a normal result is no reason to skip a scheduled cystoscopy.
Working around the BCG supply problem
Specialist reviews published in 2026 set out how clinics manage the long-running BCG shortage, including prioritizing higher-risk patients and adjusting dosing. A pooled analysis of seven studies compared heated chemotherapy delivered into the bladder against standard BCG and found broadly similar results at two years, with less painful urination. What this means for you: if BCG is unavailable, alternatives with reasonable evidence exist, and a change of plan does not mean weaker treatment. The numbers studied remain small, so decisions stay individual.
Real-world results in advanced disease
A multicenter study followed more than two hundred patients treated outside a clinical trial with the current first-line combination for advanced urothelial cancer: an antibody-drug conjugate plus an immunotherapy drug. Roughly two-thirds saw their tumors shrink. Skin reactions were the most common side effect, usually within the first few weeks. What this means for you: the combination works in everyday practice much as it did in trials, but starting it means committing to close monitoring in the first month.
Glossary
| Term | Definition |
|---|---|
| Hematuria | Blood in the urine. It is called gross or visible when you can see it, and microscopic when only a laboratory can detect it. |
| Urothelial carcinoma | The most common type of bladder cancer, arising from the urothelium, the specialized lining of the bladder and urinary tract. |
| Cystoscopy | An examination in which a thin camera is passed through the urethra to inspect the inside of the bladder directly. |
| CT urography | A computed tomography scan performed with contrast dye to image the kidneys, ureters, and bladder in detail. |
| Urine cytology | A laboratory test in which a pathologist examines cells shed into the urine to look for cancerous changes. |
| TURBT | Transurethral resection of bladder tumor: removal of a bladder tumor through the urethra, with no external incision. |
| BCG | Bacillus Calmette-Guerin, a weakened bacterium instilled into the bladder to trigger an immune response against remaining cancer cells. |
| Carcinoma in situ | A flat, high-grade cancer confined to the bladder lining. It is not raised like a typical tumor but behaves aggressively. |
| Cystectomy | Surgical removal of the bladder, usually with nearby lymph nodes, followed by rerouting of the urine. |
| Antibody-drug conjugate | A treatment that links a chemotherapy drug to an antibody so the drug is delivered mainly to cells carrying a specific target protein. |
Frequently asked questions
What are the warning signs of bladder cancer?
The most consistent warning sign is blood in the urine that appears without pain. It can make urine look pink, red, or brown, and it often comes and goes. Other signs include needing to urinate urgently or frequently, burning during urination without an infection, difficulty starting or maintaining a stream, and a feeling that the bladder has not emptied. Symptoms suggesting more advanced disease include one-sided back or flank pain, leg swelling, bone pain, and unexplained weight loss. None of these is specific to cancer, and most people with them have something else. The point is not to self-diagnose but to have the symptom evaluated rather than waiting.
Does blood in the urine always mean cancer?
No, and in most cases it does not. Urinary tract infections, kidney stones, an enlarged prostate, strenuous exercise, menstruation, some medications, and kidney disease all cause blood in the urine far more often than cancer does. Studies of people with microscopic hematuria find that only a small percentage have a urinary tract tumor. What determines how urgently it should be investigated is your risk profile: age, smoking history, and how much blood was found. Visible blood is treated more seriously than microscopic blood at any age.
How is bladder cancer detected?
Detection typically begins with a urinalysis that confirms blood, followed by imaging of the kidneys and ureters, usually CT urography. The decisive test is cystoscopy, in which a urologist looks directly at the bladder lining with a thin camera passed through the urethra. If anything abnormal is seen, a sample is taken for the pathology laboratory. Urine cytology and commercial urine marker tests can support the workup but cannot confirm or exclude the diagnosis on their own.
Can bladder cancer be cured?
Many bladder cancers are treated successfully, particularly when they are found while still confined to the lining. Non-muscle-invasive disease is generally managed with resection through the urethra followed by medication placed into the bladder, and long-term outcomes are often good. The challenge is recurrence rather than immediate danger, which is why surveillance continues for years. Muscle-invasive disease is more serious and usually requires surgery or combined chemotherapy and radiation. Outcomes depend on stage, grade, general health, and how promptly treatment began, so prognosis is a conversation to have with the treating team rather than something to read off a chart.
Is bladder cancer hereditary?
Most cases are not inherited. Bladder cancer is driven largely by acquired exposures, above all tobacco smoke and certain workplace chemicals. A family history does raise risk modestly, and a few inherited conditions, including Lynch syndrome, are associated with urinary tract tumors. If several close relatives have had bladder or upper urinary tract cancers, or cancers occurring at unusually young ages, it is reasonable to mention this to your doctor and ask whether genetic counseling would be useful.
Why do I need cystoscopy again if my urine test was normal?
Because urine tests, including cytology and commercial marker tests, miss a meaningful proportion of tumors, especially low-grade ones. Reviews comparing these tests with cystoscopy consistently find that their accuracy varies and that they are best used alongside the camera examination rather than instead of it. A normal urine result is encouraging but does not confirm that the bladder lining is clear, and recurrence is common enough after treatment that direct inspection remains the standard.
Sources
- Centers for Disease Control and Prevention — Bladder Cancer Basics, 2025 — cdc.gov
- MedlinePlus, National Library of Medicine (NIH) — Bladder Cancer, 2024 — medlineplus.gov
- Cleveland Clinic — Bladder Cancer: Symptoms, Diagnosis and Treatment — my.clevelandclinic.org
- Udedibia E, Solosky K, Macdonald EJ, et al. — Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines and Validation of the Individual Clinical Components in Risk Stratification — The Journal of Urology, 2025 — doi.org/10.1097/JU.0000000000004854
- Ramasamy RP, Chai CA, Cormio A, et al. — Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review — Investigative and Clinical Urology, 2025 — doi.org/10.4111/icu.20250262
- Kravchuk AP, Wolff I, Gilfrich C, et al. — Urine-Based Biomarker Test in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Diagnostic Test Performance — Cancers, 2024 — doi.org/10.3390/cancers16040753
- Tazegul TE, O’Donnell M, Hougen HY — Bacillus Calmette-Guerin Therapy: Optimizing Outcomes amid Challenges — Urologic Clinics of North America, 2026 — doi.org/10.1016/j.ucl.2026.03.006
- Chai Y, Zhou Y, Peng H, et al. — Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis — International Urology and Nephrology, 2026 — doi.org/10.1007/s11255-026-05008-4
- Yanagisawa T, Iwatani K, Urabe F, et al. — Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter cohort study — Urologic Oncology, 2026 — doi.org/10.1016/j.urolonc.2026.06.019
Further reading
- Lower urinary tract symptoms and what they signal
- Protein in a urine test result
- Epithelial cells found on a urine sample
- Nitrite readings on a urine dipstick
- White blood cells counted in urine
Understand your lab results with BloodSense
A urinalysis mentioning red blood cells, a urine culture that keeps coming back negative, a creatinine value, or a complete blood count showing a low hemoglobin can all feel opaque on paper. BloodSense reads those reports in plain language and shows you what each line refers to and which findings usually prompt a conversation with a clinician. It helps you understand your results and prepare better questions; it does not diagnose bladder cancer or any other condition, and it does not replace your doctor.
